financetom
Business
financetom
/
Business
/
Affirm soars as BNPL lender aims to turn profit ahead of Street targets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Affirm soars as BNPL lender aims to turn profit ahead of Street targets
Aug 31, 2024 6:34 AM

(Reuters) - Affirm shares rose 33% on Thursday after the buy-now-pay-later lender trounced estimates for quarterly results and said it expects to be profitable by the fourth quarter of next fiscal year, sooner than Wall Street had forecast.

Cash burn has been one of the biggest drags on the valuation of financial technology companies, especially for those operating in the payments sector, which also remains vulnerable to fluctuations in consumer health and interest rates.

In a letter to shareholders late on Wednesday, Affirm revealed its ambitious profitability goal and its intention to sustain it, after reporting strong fourth-quarter results.

The company's net revenue jumped 48% to $659.2 million in the three months ended June 30, beating LSEG estimates of $603.7 million.

Net loss narrowed to 14 cents per share, far smaller than Street expectations of 48 cents.

Bank of America analysts said the results reflected strong operating momentum, and Affirm's profitability forecast was "much sooner than anticipated."

The brokerage had initially expected a profit in fiscal 2026.

"We view the lower interest rate environment, scale-driven profitability outlook and Affirm's idiosyncratic growth prospects as attractive," BofA said in a note.

Gross Merchandise Volume (GMV)- the total dollar amount of all transactions on the Affirm platform - surged 31% to $7.2 billion in the quarter.

"Affirm continues to fire on all cylinders, outgrowing e-commerce and payment peers," J.P.Morgan analysts said.

Strong GMV growth at Affirm, stands in sharp contrast to the broader payments sector which flagged a hit to consumer spending in the April-to-June quarter, due to weakness in discretionary purchases, particularly among the lower-income bracket.

"(We) don't see growth as an issue for Affirm thanks to a combination of nascent BNPL adoption in the U.S. and landmark partner agreements, like the one recently announced with Apple," said Kevin Kennedy, analyst at research firm Third Bridge.

(Reporting by Manya Saini in Bengaluru; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brookdale Senior Living Reports Increase in December Occupancy
Brookdale Senior Living Reports Increase in December Occupancy
Jan 9, 2025
05:22 PM EST, 01/09/2025 (MT Newswires) -- Brookdale Senior Living ( BKD ) said Thursday that December weighted average occupancy rose 100 basis points year-over-year to 79.3%. The Q4 weighted average occupancy rose 100 basis points from a year earlier and 50 basis points from Q3, the company said. ...
Block's Ticker Symbols to Change on NYSE and ASX
Block's Ticker Symbols to Change on NYSE and ASX
Jan 9, 2025
05:19 PM EST, 01/09/2025 (MT Newswires) -- Block (SQ) said Thursday it will change its ticker symbols from SQ and SQ2 to XYZ. The ticker changes on the company's dual listings on the New York Stock Exchange and the Australian Securities Exchange are effective Jan. 21. Block's common shares will start trading under the new symbol effective Jan. 22, according...
Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials
Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials
Jan 9, 2025
05:23 PM EST, 01/09/2025 (MT Newswires) -- Repare Therapeutics ( RPTX ) said late Thursday it is refocusing its resources on advancing phase 1 clinical programs for RP-1664 in solid tumors and RP-3467 in certain types of cancer. The company also intends to seek partnerships for lunresertib and camonsertib before starting the next trials. The strategic realignment, combined with cost...
Intellia Therapeutics to Workforce by 27%, Halt Some Programs
Intellia Therapeutics to Workforce by 27%, Halt Some Programs
Jan 9, 2025
05:24 PM EST, 01/09/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) plans to cut its workforce by 27% to cuts costs and stop development of NTLA-3001 to treat alpha-1 antitrypsin deficiency-associated lung disease and halt some research-stage programs. Resources will be focused on NTLA-2002 for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis, the company said Thursday in a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved